TY - JOUR
T1 - A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD
AU - Sasaki, Takahiko
AU - Nakayama, Katsutoshi
AU - Yasuda, Hiroyasu
AU - Yamaya, Mutsuo
N1 - Funding Information:
Sasaki was partly supported by a Grant-in Aid for Scientific Research from the Ministry of Education, Science, Culture, Sports, Science and Technology (19790455) of the Japanese Government. Nakayama was partly supported by a Grant-in Aid for Scientific Research from the Ministry of Education, Science, Culture, Sports, Science and Technology (19790690) of the Japanese Government and a grant from the Japanese Foundation for Aging and Health. Yasuda was partly supported by a Grant-in Aid for Scientific Research from the Ministry of Education, Science, Culture, Sports, Science and Technology (17790524, 19689018) of the Japanese Government. Yamaya was partly supported by Health, Labour Sciences Research Grants for Research on Measures for Intractable Diseases from the Ministry of Health, Labour and Welfare (H20nannchiippann35) and the Respiratory Failure Research Group form the Ministry of Health, Labour and Welfare, Japan.
PY - 2011/4
Y1 - 2011/4
N2 - Acute exacerbations of chronic obstructive pulmonary disease (COPD), an acute worsening of respiratory symptoms, generally result in a poor prognosis. Successful prevention and management of such exacerbations is thus important for patient care. Viral infection, primarily with rhinovirus (RV), is the foremost cause of exacerbations in COPD patients. Proton pump inhibitors (PPIs) have been reported to inhibit RV infection in human airway epithelial cells in vitro. Furthermore, clinical trials of PPIs in patients with COPD resulted in a reduction in rates of both common cold and COPD exacerbations. In this review, we discuss the significance of COPD exacerbations, summarize a published trial of the effect of low-dose PPIs on COPD exacerbations, and postulate a mechanism for this effect.
AB - Acute exacerbations of chronic obstructive pulmonary disease (COPD), an acute worsening of respiratory symptoms, generally result in a poor prognosis. Successful prevention and management of such exacerbations is thus important for patient care. Viral infection, primarily with rhinovirus (RV), is the foremost cause of exacerbations in COPD patients. Proton pump inhibitors (PPIs) have been reported to inhibit RV infection in human airway epithelial cells in vitro. Furthermore, clinical trials of PPIs in patients with COPD resulted in a reduction in rates of both common cold and COPD exacerbations. In this review, we discuss the significance of COPD exacerbations, summarize a published trial of the effect of low-dose PPIs on COPD exacerbations, and postulate a mechanism for this effect.
KW - chronic obstructive pulmonary disease (COPD)
KW - common cold
KW - exacerbations
KW - proton pump inhibitors (PPIs)
KW - rhinovirus
UR - http://www.scopus.com/inward/record.url?scp=79953326956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953326956&partnerID=8YFLogxK
U2 - 10.1177/1753465810392264
DO - 10.1177/1753465810392264
M3 - Review article
C2 - 21285157
AN - SCOPUS:79953326956
SN - 1753-4658
VL - 5
SP - 91
EP - 103
JO - Therapeutic Advances in Respiratory Disease
JF - Therapeutic Advances in Respiratory Disease
IS - 2
ER -
